Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02345772 · ClinicalTrials.gov registry record · Phase 1
Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy
A Phase 1 study, sponsored by Western Regional Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT02345772: Clinical Trial Phase 1 study, sponsored by Western Regional Medical Center.
NCT02345772 is a Phase 1 study that was terminated before completion, run by Western Regional Medical Center. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02345772, a Phase 1 study, was terminated before completion, sponsored by Western Regional Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
Hormonal therapy administered before surgery in ER-positive and HER2-positive patients with breast cancer.
Primary Outcome
To determine pathological complete remission rate at the time of surgery in ER-positive and HER2-positive breast cancer patients undergoing neoadjuvant chemoimmunotherapy (docetaxel, trastuzumab, pertuzumab) concurrently with neoadjuvant hormonal therapy with fulvestrant. Note: pCR, defined as the absence of invasive neoplastic cells of the primary tumor in the breast, remaining in-situ lesions are allowed, ypT0-is;
Interventions
- DRUG Docetaxel
- DRUG fulvestrant 500 mg
- DRUG Trastuzumab (H, 8mg/kg
- DRUG Pertuzumab (P, 840 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-11 |
| Phase | Phase 1 |
Why NCT02345772 stopped before completion
NCT02345772 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 4 interventions - of which Docetaxel is the first listed.
NCT02345772 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02345772 about?
NCT02345772 is a clinical study titled "Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy". Hormonal therapy administered before surgery in ER-positive and HER2-positive patients with breast cancer.
What is the current status of trial NCT02345772?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2014-07. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02345772?
The interventions under investigation include: Docetaxel (DRUG), fulvestrant 500 mg (DRUG), Trastuzumab (H, 8mg/kg (DRUG), Pertuzumab (P, 840 mg (DRUG).
Who is sponsoring clinical trial NCT02345772?
This trial is sponsored by Western Regional Medical Center, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02345772's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia